Podcast Music Movie Game Book
  1. 🎧Podcast
  2. 🎧U.S. Food and Drug Administration, Center for Drug Evaluation and Research
  3. FDA D.I.S.C.O. Burst Edition: Tepmetko (tepotinib) and Ukoniq (umbralisib)

FDA D.I.S.C.O. Burst Edition: Tepmetko (tepotinib) and Ukoniq (umbralisib)

Release Date:

Tepmetko (tepotinib): metastatic NSCLC harboring mesenchymal-epithelial transition exon 14 skipping alterations. Ukoniq (umbralisib): relapsed/refractory marginal zone lymphoma with at least 1 prior anti-CD20 regimen & relapsed/refractory follicular lymphoma with at least 3 prior systemic therapies.

FDA D.I.S.C.O. Burst Edition: Tepmetko (tepotinib) and Ukoniq (umbralisib)
Title
FDA D.I.S.C.O. Burst Edition: Tepmetko (tepotinib) and Ukoniq (umbralisib)
Copyright
Release Date

flashback